SCHEMBL7144474

SCHEMBL7144474

O=C(O)CCN(C(=O)[C@@H]1C[C@@H](S)CN1S(=O)(=O)c1ccc2ccccc2c1)C1CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 6/20 0.54
MME P08473 2/20 0.54
ACE P12821 2/20 0.54
CCR4 P51679 5/20 0.44
AKR1C3 P42330 4/20 0.42
AKR1C1 Q04828 1/20 0.41
EIF2AK3 Q9NZJ5 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144476 1.00 ECE1 (0.54) ECE1MMEACECCR4AKR1C3
SCHEMBL7136543 0.88 ECE1 (0.52) ECE1MMEACECCR4AKR1C3
SCHEMBL7136546 0.88 ECE1 (0.52) ECE1MMEACECCR4AKR1C3
SCHEMBL7146136 0.87 ECE1 (0.64) ECE1MMEACECCR4AKR1C3
SCHEMBL7146140 0.87 ECE1 (0.64) ECE1MMEACECCR4AKR1C3
SCHEMBL7138165 0.84 ECE1 (0.54) ECE1MMEACECCR4AKR1C3
SCHEMBL7138164 0.84 ECE1 (0.54) ECE1MMEACECCR4AKR1C3
SCHEMBL7149129 0.82 ECE1 (0.48) ECE1MMEACECCR4AKR1C3
SCHEMBL7135704 0.81 ECE1 (0.69) ECE1MMEACECCR4AKR1C3
SCHEMBL7135702 0.81 ECE1 (0.69) ECE1MMEACECCR4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ECE1 4/4885MME 99/4885ACE 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.